0000811212 ThermoGenesis Holdings, Inc. false --12-31 Q3 2021 212,000 214,000 0.001 0.001 2,000,000 2,000,000 0 0 0 0 0.001 0.001 350,000,000 350,000,000 11,911,784 11,911,784 8,934,952 8,934,952 5 2 2 4 5 0.25 1 1 1 1 0.25 1 1 1 1 0.25 1 1 1 1 0.25 1 1 1 1 0.5 1 1 1 1 750,000 March 6, 2022 1,583,000 March 6, 2022 4,065,000 July 31, 2022 267,000 July 31, 2022 507,000 60,000 180,000 1 2 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants remained outstanding but unvested until they expired in February 2021. Represents the minimum purchase requirements related to the Company AXP distributor in China Accumulated other comprehensive loss. 00008112122021-01-012021-09-30 xbrli:shares 00008112122021-11-12 thunderdome:item iso4217:USD 00008112122021-09-30 00008112122020-12-31 iso4217:USDxbrli:shares 00008112122021-07-012021-09-30 00008112122020-07-012020-09-30 00008112122020-01-012020-09-30 0000811212us-gaap:CommonStockMember2020-12-31 0000811212us-gaap:AdditionalPaidInCapitalMember2020-12-31 0000811212us-gaap:RetainedEarningsMember2020-12-31 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-31 0000811212us-gaap:NoncontrollingInterestMember2020-12-31 0000811212us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-31 00008112122021-01-012021-03-31 0000811212us-gaap:CommonStockMemberthmo:AtTheMarketOfferingAgreementMember2021-01-012021-03-31 0000811212us-gaap:AdditionalPaidInCapitalMemberthmo:AtTheMarketOfferingAgreementMember2021-01-012021-03-31 0000811212thmo:AtTheMarketOfferingAgreementMember2021-01-012021-03-31 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-31 0000811212us-gaap:RetainedEarningsMember2021-01-012021-03-31 0000811212us-gaap:NoncontrollingInterestMember2021-01-012021-03-31 0000811212us-gaap:CommonStockMember2021-03-31 0000811212us-gaap:AdditionalPaidInCapitalMember2021-03-31 0000811212us-gaap:RetainedEarningsMember2021-03-31 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-31 0000811212us-gaap:NoncontrollingInterestMember2021-03-31 00008112122021-03-31 0000811212us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-30 00008112122021-04-012021-06-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-30 0000811212us-gaap:RetainedEarningsMember2021-04-012021-06-30 0000811212us-gaap:NoncontrollingInterestMember2021-04-012021-06-30 0000811212us-gaap:CommonStockMember2021-06-30 0000811212us-gaap:AdditionalPaidInCapitalMember2021-06-30 0000811212us-gaap:RetainedEarningsMember2021-06-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-30 0000811212us-gaap:NoncontrollingInterestMember2021-06-30 00008112122021-06-30 0000811212us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-30 0000811212us-gaap:RetainedEarningsMember2021-07-012021-09-30 0000811212us-gaap:NoncontrollingInterestMember2021-07-012021-09-30 0000811212us-gaap:CommonStockMember2021-09-30 0000811212us-gaap:AdditionalPaidInCapitalMember2021-09-30 0000811212us-gaap:RetainedEarningsMember2021-09-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-30 0000811212us-gaap:NoncontrollingInterestMember2021-09-30 0000811212us-gaap:CommonStockMember2019-12-31 0000811212us-gaap:AdditionalPaidInCapitalMember2019-12-31 0000811212us-gaap:RetainedEarningsMember2019-12-31 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-31 0000811212us-gaap:NoncontrollingInterestMember2019-12-31 00008112122019-12-31 0000811212us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-31 00008112122020-01-012020-03-31 0000811212us-gaap:CommonStockMember2020-01-012020-03-31 0000811212thmo:BoyalifeAssetHoldingIIMemberus-gaap:CommonStockMember2020-01-012020-03-31 0000811212thmo:BoyalifeAssetHoldingIIMemberus-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-31 0000811212thmo:BoyalifeAssetHoldingIIMember2020-01-012020-03-31 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-31 0000811212us-gaap:RetainedEarningsMember2020-01-012020-03-31 0000811212us-gaap:NoncontrollingInterestMember2020-01-012020-03-31 0000811212us-gaap:CommonStockMember2020-03-31 0000811212us-gaap:AdditionalPaidInCapitalMember2020-03-31 0000811212us-gaap:RetainedEarningsMember2020-03-31 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-31 0000811212us-gaap:NoncontrollingInterestMember2020-03-31 00008112122020-03-31 0000811212us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-30 00008112122020-04-012020-06-30 0000811212us-gaap:CommonStockMember2020-04-012020-06-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-04-012020-06-30 0000811212us-gaap:RetainedEarningsMember2020-04-012020-06-30 0000811212us-gaap:NoncontrollingInterestMember2020-04-012020-06-30 0000811212us-gaap:CommonStockMember2020-06-30 0000811212us-gaap:AdditionalPaidInCapitalMember2020-06-30 0000811212us-gaap:RetainedEarningsMember2020-06-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-30 0000811212us-gaap:NoncontrollingInterestMember2020-06-30 00008112122020-06-30 0000811212us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-30 0000811212us-gaap:CommonStockMember2020-07-012020-09-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-30 0000811212us-gaap:RetainedEarningsMember2020-07-012020-09-30 0000811212us-gaap:NoncontrollingInterestMember2020-07-012020-09-30 0000811212us-gaap:CommonStockMember2020-09-30 0000811212us-gaap:AdditionalPaidInCapitalMember2020-09-30 0000811212us-gaap:RetainedEarningsMember2020-09-30 0000811212us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-30 0000811212us-gaap:NoncontrollingInterestMember2020-09-30 00008112122020-09-30 0000811212thmo:ConversionOfRelatedPartyConvertiblePromissoryNoteIntoCommonStockMember2020-01-012020-09-30 0000811212thmo:ConversionOfJanuary2019AmendedNotesToCommonStockMember2020-01-012020-09-30 xbrli:pure 0000811212thmo:CARTXpressMember2021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:AxpMember2021-07-012021-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:AxpMember2021-07-012021-09-30 0000811212thmo:DeviceMemberthmo:AxpMember2021-07-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:BioarchiveMember2021-07-012021-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:BioarchiveMember2021-07-012021-09-30 0000811212thmo:DeviceMemberthmo:BioarchiveMember2021-07-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:CARTXpressMember2021-07-012021-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:CARTXpressMember2021-07-012021-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:CARTXpressMember2021-07-012021-09-30 0000811212thmo:DeviceMemberthmo:CARTXpressMember2021-07-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:ManualDisposablesMember2021-07-012021-09-30 0000811212thmo:DeviceMemberthmo:ManualDisposablesMember2021-07-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2021-07-012021-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2021-07-012021-09-30 0000811212thmo:DeviceMemberthmo:OtherSubsegmentsMember2021-07-012021-09-30 0000811212thmo:DeviceRevenueMember2021-07-012021-09-30 0000811212us-gaap:ServiceMember2021-07-012021-09-30 0000811212thmo:OtherMember2021-07-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:AxpMember2021-01-012021-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:AxpMember2021-01-012021-09-30 0000811212thmo:DeviceMemberthmo:AxpMember2021-01-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:BioarchiveMember2021-01-012021-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:BioarchiveMember2021-01-012021-09-30 0000811212thmo:DeviceMemberthmo:BioarchiveMember2021-01-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:CARTXpressMember2021-01-012021-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:CARTXpressMember2021-01-012021-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:CARTXpressMember2021-01-012021-09-30 0000811212thmo:DeviceMemberthmo:CARTXpressMember2021-01-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:ManualDisposablesMember2021-01-012021-09-30 0000811212thmo:DeviceMemberthmo:ManualDisposablesMember2021-01-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2021-01-012021-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2021-01-012021-09-30 0000811212thmo:DeviceMemberthmo:OtherSubsegmentsMember2021-01-012021-09-30 0000811212thmo:DeviceRevenueMember2021-01-012021-09-30 0000811212us-gaap:ServiceMember2021-01-012021-09-30 0000811212thmo:OtherMember2021-01-012021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:AxpMember2020-07-012020-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:AxpMember2020-07-012020-09-30 0000811212thmo:DeviceMemberthmo:AxpMember2020-07-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:BioarchiveMember2020-07-012020-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:BioarchiveMember2020-07-012020-09-30 0000811212thmo:DeviceMemberthmo:BioarchiveMember2020-07-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:CARTXpressMember2020-07-012020-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:CARTXpressMember2020-07-012020-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:CARTXpressMember2020-07-012020-09-30 0000811212thmo:DeviceMemberthmo:CARTXpressMember2020-07-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:ManualDisposablesMember2020-07-012020-09-30 0000811212thmo:DeviceMemberthmo:ManualDisposablesMember2020-07-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2020-07-012020-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2020-07-012020-09-30 0000811212thmo:DeviceMemberthmo:OtherSubsegmentsMember2020-07-012020-09-30 0000811212thmo:DeviceRevenueMember2020-07-012020-09-30 0000811212us-gaap:ServiceMember2020-07-012020-09-30 0000811212thmo:OtherMember2020-07-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:AxpMember2020-01-012020-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:AxpMember2020-01-012020-09-30 0000811212thmo:DeviceMemberthmo:AxpMember2020-01-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:BioarchiveMember2020-01-012020-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:BioarchiveMember2020-01-012020-09-30 0000811212thmo:DeviceMemberthmo:BioarchiveMember2020-01-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:CARTXpressMember2020-01-012020-09-30 0000811212us-gaap:ServiceMemberthmo:DeviceMemberthmo:CARTXpressMember2020-01-012020-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:CARTXpressMember2020-01-012020-09-30 0000811212thmo:DeviceMemberthmo:CARTXpressMember2020-01-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:ManualDisposablesMember2020-01-012020-09-30 0000811212thmo:DeviceMemberthmo:ManualDisposablesMember2020-01-012020-09-30 0000811212thmo:DeviceRevenueMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2020-01-012020-09-30 0000811212thmo:OtherMemberthmo:DeviceMemberthmo:OtherSubsegmentsMember2020-01-012020-09-30 0000811212thmo:DeviceMemberthmo:OtherSubsegmentsMember2020-01-012020-09-30 0000811212thmo:DeviceRevenueMember2020-01-012020-09-30 0000811212us-gaap:ServiceMember2020-01-012020-09-30 0000811212thmo:OtherMember2020-01-012020-09-30 utr:Y 0000811212thmo:SupplyAgreementMember2019-08-302019-08-30 0000811212thmo:SupplyAgreementMember2019-08-30 0000811212srt:MaximumMemberthmo:SupplyAgreementMember2019-08-302019-08-30 0000811212thmo:ExclusivityFeeMember2019-08-30 0000811212thmo:ExclusivityFeeMember2021-07-012021-09-30 0000811212thmo:ExclusivityFeeMember2021-01-012021-09-30 0000811212thmo:ExclusivityFeeMember2019-08-302019-08-30 0000811212thmo:ExclusivityFeeMember2021-09-30 0000811212thmo:DistributionAgreementWithAxpDistributorInChinaMember2021-01-012021-09-30 0000811212thmo:DistributionAgreementWithAxpDistributorInChinaMember2021-09-30 0000811212thmo:DeviceRevenueMemberthmo:DistributionAgreementWithAxpDistributorInChinaMember2021-01-012021-09-30 0000811212us-gaap:ServiceMember2021-10-012021-09-30 0000811212us-gaap:ServiceMember2022-01-012021-09-30 0000811212us-gaap:ServiceMember2023-01-012021-09-30 0000811212us-gaap:ServiceMember2024-01-012021-09-30 0000811212us-gaap:ServiceMember2025-01-012021-09-30 0000811212us-gaap:ServiceMember2021-09-30 0000811212thmo:ClinicalRevenueMember2021-10-012021-09-30 0000811212thmo:ClinicalRevenueMember2022-01-012021-09-30 0000811212thmo:ClinicalRevenueMember2023-01-012021-09-30 0000811212thmo:ClinicalRevenueMember2024-01-012021-09-30 0000811212thmo:ClinicalRevenueMember2025-01-012021-09-30 0000811212thmo:ClinicalRevenueMember2021-09-30 0000811212thmo:DeviceRevenueMember2021-10-012021-09-30 0000811212thmo:DeviceRevenueMember2022-01-012021-09-30 0000811212thmo:DeviceRevenueMember2023-01-012021-09-30 0000811212thmo:DeviceRevenueMember2024-01-012021-09-30 0000811212thmo:DeviceRevenueMember2025-01-012021-09-30 0000811212thmo:DeviceRevenueMember2021-09-30 0000811212thmo:ExclusivityFeeMember2021-10-012021-09-30 0000811212thmo:ExclusivityFeeMember2022-01-012021-09-30 0000811212thmo:ExclusivityFeeMember2023-01-012021-09-30 0000811212thmo:ExclusivityFeeMember2024-01-012021-09-30 0000811212thmo:ExclusivityFeeMember2025-01-012021-09-30 00008112122021-10-012021-09-30 00008112122022-01-012021-09-30 00008112122023-01-012021-09-30 00008112122024-01-012021-09-30 00008112122025-01-012021-09-30 0000811212us-gaap:ConvertibleDebtSecuritiesMember2021-01-012021-09-30 0000811212us-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-09-30 0000811212thmo:VestedSeriesAWarrantsMember2020-01-012020-09-30 0000811212thmo:UnvestedSeriesAWarrantsMember2020-01-012020-09-30 0000811212thmo:WarrantOtherMember2021-01-012021-09-30 0000811212thmo:WarrantOtherMember2020-01-012020-09-30 0000811212us-gaap:EmployeeStockOptionMember2021-01-012021-09-30 0000811212us-gaap:EmployeeStockOptionMember2020-01-012020-09-30 0000811212thmo:HealthbanksBiotechMemberthmo:ImmunecyteMember2019-11-26 0000811212thmo:ImmunecyteMember2019-11-26 0000811212thmo:HealthbanksBiotechMemberthmo:ImmunecyteMember2020-09-30 0000811212thmo:ImmunecyteMember2020-09-30 0000811212thmo:PrivateInstitutionMemberthmo:ImmunecyteMember2020-09-30 0000811212thmo:BoyalifesCellularTherapyDivisionMemberthmo:ImmuneCyteAndShangaiKDwinfoTechnologyCoLtdMember2021-03-012021-03-31 0000811212thmo:BoyalifesCellularTherapyDivisionMemberthmo:ImmunecyteMember2021-03-012021-03-31 0000811212thmo:ImmunecyteMember2021-09-30 0000811212thmo:ImmunecyteMember2021-01-012021-09-30 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2017-03-31 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2020-04-28 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2020-12-31 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2021-01-012021-01-31 0000811212us-gaap:ConvertibleDebtMemberthmo:BoyalifeAssetHoldingIIMember2018-04-16 0000811212us-gaap:ConvertibleDebtMemberthmo:BoyalifeAssetHoldingIIMember2018-12-31 0000811212us-gaap:ConvertibleDebtMemberthmo:BoyalifeAssetHoldingIIMember2021-01-012021-09-30 0000811212us-gaap:ConvertibleDebtMemberthmo:BoyalifeAssetHoldingIIMember2021-09-30 0000811212us-gaap:ConvertibleDebtMemberthmo:BoyalifeAssetHoldingIIMember2020-01-012020-12-31 0000811212us-gaap:ConvertibleDebtMemberthmo:BoyalifeAssetHoldingIIMember2020-12-31 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2021-07-012021-09-30 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2021-01-012021-09-30 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2020-07-012020-09-30 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2020-01-012020-09-30 0000811212us-gaap:RevolvingCreditFacilityMemberthmo:BoyalifeAssetHoldingIIMember2021-09-30 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2019-07-23 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMembersrt:MaximumMember2019-07-23 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2019-07-232019-07-23 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMembersrt:MinimumMember2019-07-23 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2021-01-012021-09-30 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2021-09-30 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2020-01-012020-12-31 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2020-12-31 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2021-07-012021-09-30 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2020-07-012020-09-30 0000811212thmo:TheJuly2019NoteMemberus-gaap:ConvertibleDebtMember2020-01-012020-09-30 0000811212thmo:CurrentLiabilitiesMember2021-09-30 0000811212thmo:CurrentLiabilitiesMember2020-12-31 0000811212us-gaap:AccountingStandardsUpdate201602Member2019-01-01 00008112122020-07-13 0000811212srt:MinimumMember2021-01-012021-09-30 0000811212srt:MaximumMember2021-01-012021-09-30 0000811212thmo:PaycheckProtectionProgramCaresActMember2020-04-212020-04-21 0000811212thmo:PaycheckProtectionProgramCaresActMember2021-01-012021-09-30 0000811212thmo:AtTheMarketOfferingAgreementMember2019-12-13 0000811212thmo:AtTheMarketOfferingAgreementMember2020-05-19 0000811212thmo:AtTheMarketOfferingAgreementMember2019-12-132021-09-30 0000811212thmo:AtTheMarketOfferingAgreementMember2021-09-30 0000811212thmo:AtTheMarketOfferingAgreementMember2021-01-012021-09-30 0000811212srt:ExecutiveOfficerMember2021-05-012021-05-31 0000811212us-gaap:EmployeeStockOptionMembersrt:ExecutiveOfficerMember2021-04-012021-06-30 0000811212us-gaap:CostOfSalesMember2021-07-012021-09-30 0000811212us-gaap:CostOfSalesMember2020-07-012020-09-30 0000811212us-gaap:CostOfSalesMember2021-01-012021-09-30 0000811212us-gaap:CostOfSalesMember2020-01-012020-09-30 0000811212us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-30 0000811212us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-30 0000811212us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-30 0000811212us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-30 0000811212us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-30 0000811212us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-30 0000811212us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-30 0000811212us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-30 00008112122020-01-012020-12-31 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer1Member2021-07-012021-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer1Member2020-07-012020-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer2Member2021-07-012021-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer2Member2020-07-012020-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer3Member2021-07-012021-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer3Member2020-07-012020-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer1Member2021-01-012021-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer1Member2020-01-012020-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer2Member2021-01-012021-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer2Member2020-01-012020-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer3Member2021-01-012021-09-30 0000811212us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMemberthmo:Customer3Member2020-01-012020-09-30 0000811212us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2021-01-012021-09-30 0000811212us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberthmo:TwoCustomersMember2021-01-012021-09-30 0000811212us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2020-01-012020-12-31 0000811212us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMemberthmo:ThreeCustomersMember2020-01-012020-12-31
 

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 10-Q

 

☒         Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended September 30, 2021.

 

or

 

☐         Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition from _____________ to _______________.

 

Commission File Number: 333-82900

ThermoGenesis Holdings, Inc.

(Exact name of registrant as specified in its charter)

     

Delaware

(State of incorporation)

 

94-3018487

(I.R.S. Employer Identification No.)

     

2711 Citrus Road

Rancho Cordova, California 95742

(Address of principal executive offices) (Zip Code)

 

(916) 858-5100

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common Stock, $.001 par value

THMO

Nasdaq Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes ☐ No ☒

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class

 

Outstanding at November 12, 2021

Common stock, $.001 par value

 

11,911,784

 

 
 

 

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

ThermoGenesis Holdings, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

 

   

September 30,

2021

   

December 31,

2020

 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 7,634,000     $ 7,161,000  

Accounts receivable, net of allowance for doubtful accounts of $212,000 at September 30, 2021 ($214,000 at December 31, 2020)

    2,571,000       1,382,000  

Inventories

    5,538,000       5,877,000  

Prepaid expenses and other current assets

    1,138,000       878,000  

Total current assets

    16,881,000       15,298,000  
                 

Inventories, non-current

    1,784,000       1,221,000  

Equipment and leasehold improvements, net

    1,339,000       1,424,000  

Right-of-use operating lease assets, net

    614,000       730,000  

Goodwill

    781,000       781,000  

Other intangible assets, net

    1,326,000       1,358,000  

Other assets

    48,000       48,000  

Total assets

  $ 22,773,000     $ 20,860,000  
                 

LIABILITIES AND STOCKHOLDERS EQUITY

               

Current liabilities:

               

Accounts payable

  $ 1,502,000     $ 1,366,000  

Accrued payroll and related expenses

    461,000       349,000  

Deferred revenue – short-term

    943,000       608,000  

Convertible promissory note – related party, net

    8,417,000       --  

Interest payable – related party

    1,668,000       2,082,000  

Note payable – short-term

    --       447,000  

Convertible promissory note, net

    733,000       --  

Other current liabilities

    1,011,000       1,291,000  

Total current liabilities

    14,735,000       6,143,000  
                 

Convertible promissory note – related party, net

    --       5,935,000  

Convertible promissory note, net

    --       493,000  

Note payable

    --       199,000  

Operating lease obligations – long-term

    455,000       604,000  

Deferred revenue – long-term

    1,395,000       1,596,000  

Other noncurrent liabilities

    20,000       20,000  

Total liabilities

    16,605,000       14,990,000  
                 

Commitments and contingencies

                 
                 

Stockholders’ equity:

               

Preferred stock, $0.001 par value; 2,000,000 shares authorized, none outstanding

    --       --  

Common stock, $0.001 par value; 350,000,000 shares authorized; 11,911,784 issued and outstanding (8,934,952 at December 31, 2020)

    12,000       9,000  

Additional paid in capital

    268,336,000       259,058,000  

Accumulated deficit

    (262,009,000 )     (253,283,000 )

Accumulated other comprehensive loss

    28,000       16,000  

Total ThermoGenesis Holdings, Inc. stockholders’ equity

    6,367,000       5,800,000  
                 

Noncontrolling interests

    (199,000 )     70,000  

Total equity

    6,168,000       5,870,000  

Total liabilities and equity

  $ 22,773,000     $ 20,860,000  

 

See accompanying notes.

 

 

 

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

 

   

Three Months Ended
September 30,

   

Nine Months Ended

September 30,

 
   

2021

   

2020

   

2021

   

2020

 
                                 

Net revenues

  $ 3,158,000     $ 2,355,000     $ 6,876,000     $ 7,797,000  

Cost of revenues

    2,043,000       844,000       4,067,000       7,426,000  
                                 

Gross profit (loss)

    1,115,000       1,511,000       2,809,000       371,000  
                                 

Expenses:

                               

Selling, general and administrative

    1,677,000       1,844,000       7,171,000       5,913,000  

Research and development

    543,000       750,000       1,544,000       1,937,000  
                                 

Total operating expenses

    2,220,000       2,594,000       8,715,000       7,850,000  
                                 

Loss from operations

    (1,105,000 )     (1,083,000 )     (5,906,000 )     (7,479,000 )
                                 

Other expenses:

                               

Interest expense

    (1,530,000 )     (1,531,000 )     (4,573,000 )     (6,377,000 )

Gain/(loss) on extinguishment of debt

    --       --       652,000       --  

Other income/(expense)

    843,000       5,000       833,000       (6,000 )
                                 

Total other expense

    (687,000 )     (1,526,000 )     (3,088,000 )     (6,383,000 )
                                 

Net loss

    (1,792,000 )     (2,609,000 )     (8,994,000 )     (13,862,000 )
                                 

Loss attributable to noncontrolling interests

    (18,000 )     (146,000 )     (269,000 )     (360,000 )

Net loss attributable to common stockholders

  $ (1,774,000 )   $ (2,463,000 )   $ (8,725,000 )   $ (13,502,000 )
                                 

COMPREHENSIVE LOSS

                               

Net loss

  $ (1,792,000 )   $ (2,609,000 )   $ (8,994,000 )   $ (13,862,000 )

Other comprehensive loss:

                               

Foreign currency translation adjustments gain (loss)

    (1,000 )     (19,000 )     12,000       20,000  

Comprehensive loss

    (1,793,000 )     (2,628,000 )     (8,982,000 )     (13,842,000 )

Comprehensive loss attributable to noncontrolling interests

    (18,000 )     (146,000 )     (269,000 )     (360,000 )

Comprehensive loss attributable to common stockholders

  $ (1,775,000 )   $ (2,482,000 )   $ (8,713,000 )   $ (13,482,000 )
                                 

Per share data:

                               
                                 

Basic and diluted net loss per common share

  $ (0.15 )   $ (0.37 )   $ (0.74 )   $ (2.36 )
                                 

Weighted average common shares outstanding – basic and diluted

    11,911,784       6,711,664       11,757,211       5,728,105  

 

See accompanying notes.

 

 

 

 

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Equity

For the Three and Nine Months Ended September 30, 2021 (Unaudited)

 

   

Shares

   

Common

Stock

   

Paid in Capital

in Excess of

Par

   

Accumulated

Deficit

   

AOCL*

   

Non-

Controlling

interests

   

Total Equity

 

Balance at January 1, 2021

    8,934,952     $ 9,000     $ 259,058,000     $ (253,283,000 )   $ 16,000     $ 70,000     $ 5,870,000  
                                                         

Stock-based compensation expense

    --       --       258,000       --       --       --       258,000  

Issuance of common stock via at- the-market offering, net

    2,976,832       3,000       6,829,000       --       --       --       6,832,000  

Foreign currency translation gain

    --       --       --       --       1,000       --       1,000  

Net loss

    --       --       --       (2,413,000 )     --       (118,000 )     (2,531,000 )

Balance at March 31, 2021

    11,911,784     $ 12,000     $ 266,145,000     $ (255,696,000 )   $ 17,000     $ (48,000 )   $ 10,430,000  
                                                         

Stock-based compensation expense

    --       --       2,099,000       --       --       --       2,099,000  

Foreign currency translation gain

    --       --       --       --       12,000       --       12,000  

Net loss

    --       --       --       (4,539,000 )     --       (133,000 )     (4,672,000 )

Balance at June 30, 2021

    11,911,784     $ 12,000     $ 268,244,000     $ (260,235,000 )   $ 29,000     $ (181,000 )   $ 7,869,000  
                                                         

Stock-based compensation expense

    --       --       92,000       --       --       --       92,000  

Foreign currency translation gain

    --       --       --       --       (1,000 )     --       (1,000 )

Net loss

    --       --       --       (1,774,000 )     --       (18,000 )     (1,792,000 )

Balance at September 30, 2021

    11,911,784     $ 12,000     $ 268,336,000     $ (262,009,000 )   $ 28,000     $ (199,000 )   $ 6,168,000  

 

* Accumulated other comprehensive loss.

 

 

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Equity

For the Three and Nine Months Ended September 30, 2020 (Unaudited)

 

    Shares    

Common

Stock

   

Paid in Capital

in Excess of

Par

   

Accumulated

Deficit

    AOCL*    

Non-

Controlling

interests

    Total Equity  

Balance at January 1, 2020

    2,843,601     $ 3,000     $ 237,313,000     $ (236,932,000 )   $ 2,000     $ 530,000     $ 916,000  
                                                         

Stock-based compensation expense

    --       --       67,000       --       --       --       67,000  

Exercise of pre-funded warrants

    100,000       --       10,000       --       --       --       10,000  

Exercise of warrants

    7,866       --       47,000       --       --       --       47,000  

Discount due to beneficial conversion features

    --       --       1,869,000       --       --       --       1,869,000  

Conversion of related party note payable to common stock

    1,666,670       2,000       2,998,000       --       --       --       3,000,000  

Conversion of note payable to common stock

    100,000       --       180,000       --       --       --       180,000  

Issuance of common stock, net

    1,050,748       1,000       3,220,000       --       --       --       3,221,000  

Foreign currency translation gain

    --       --       --       --       38,000       --       38,000  

Net loss

    --       --       --       (4,602,000 )     --       (141,000 )     (4,743,000 )

Balance at March 31, 2020

    5,768,885     $ 6,000     $ 245,704,000     $ (241,534,000 )   $ 40,000     $ 389,000     $ 4,605,000  
                                                         

Stock-based compensation expense

    --       --       314,000       --       --       --       314,000  

Exercise of pre-funded warrants

    224,445               22,000       --       --       --       22,000  

Exercise of warrants

    267,271       --       1,604,000       --       --       --       1,604,000  

Discount due to beneficial conversion features

    --       --       3,112,000       --       --       --       3,112,000  

Conversion of note payable to common stock

    104,445       1,000       188,000       --       --       --       189,000  

Issuance of Common Stock, net

    344,419       --       1,993,000       --       --       --       1,993,000  

Foreign currency translation gain

    --       --       --       --       1,000       --       1,000  

Net loss

    --       --       --       (6,437,000 )             (73,000 )     (6,510,000 )

Balance at June 30, 2020

    6,709,465     $ 7,000     $ 252,937,000     $ (247,971,000 )   $ 41,000     $ 316,000     $ 5,330,000  
                                                         

Stock-based compensation expense

    --       --       234,000       --       --       --       234,000  

Issuance of Common Stock, net

    122,575       --       366,000       --       --       --       366,000  

Foreign currency translation gain

    --       --       --       --       (19,000 )     --       (19,000 )

Net loss

    --       --       --       (2,463,000 )             (146,000 )     (2,609,000 )

Balance at September 30, 2020

    6,832,040     $ 7,000     $ 253,537,000     $ (250,434,000 )   $ 22,000     $ 170,000     $ 3,302,000  

 

* Accumulated other comprehensive loss.

See accompanying notes.

 

 

 

ThermoGenesis Holdings, Inc.

Condensed Consolidated Statements of Cash Flows (Unaudited)

 

   

Nine Months Ended

September 30,

 
   

2021

   

2020

 

Cash flows from operating activities:

               

Net loss

  $ (8,994,000 )   $ (13,862,000 )

Adjustments to reconcile net loss to net cash used in operating activities:

               

Depreciation and amortization

    477,000       569,000  

Stock based compensation expense

    2,449,000       615,000  

Amortization of debt discount/premium, net

    2,723,000       2,165,000  

Amortization of accelerated debt discount due to conversion

    --       2,486,000  

Reserve for excess and slow-moving inventories

    336,000       4,036,000  

Reserve for bad debt expense

    --       (6,000 )

Loss on disposal of equipment

    --       118,000  

Gain on extinguishment of debt

    (652,000 )     --  

Net change in operating assets and liabilities:

               

Accounts receivable

    (1,190,000 )     (414,000 )

Inventories

    (742,000 )     (6,086,000 )

Prepaid expenses and other assets

    (260,000 )     6,000  

Accounts payable

    145,000       223,000  

Interest payable - related party

    (413,000 )     (350,000 )

Accrued payroll and related expenses

    111,000       225,000  

Deferred revenue – short-term

    334,000       80,000  

Other current liabilities

    (271,000 )     (1,326,000 )

Long-term deferred revenue and other noncurrent liabilities

    (347,000 )     (338,000 )
                 

Net cash used in operating activities

    (6,294,000 )     (11,859,000 )
                 

Cash flows from investing activities:

               

Capital expenditures

    (64,000 )     (23,000 )
                 

Net cash used in investing activities

    (64,000 )     (23,000 )
                 

Cash flows from financing activities:

               
                 

Proceeds from convertible promissory note-related party

    --       4,287,000  

Payments on financing lease obligations

    --       (32,000 )

Proceeds from issuance of common stock, net of expenses

    6,832,000       5,580,000  

Proceeds from exercise of options, warrants and pre-funded warrants

    --       1,683,000  

Proceeds from note payable

    --       646,000  
                 

Net cash provided by financing activities

    6,832,000       12,164,000  
                 

Effects of foreign currency rate changes on cash and cash equivalents

    (1,000 )     (3,000 )

Net increase (decrease) in cash, cash equivalents and restricted cash

    473,000       279,000  
                 

Cash, cash equivalents and restricted cash at beginning of period

    7,161,000       4,157,000  

Cash, cash equivalents and restricted cash at end of period

  $ 7,634,000     $ 4,436,000  
                 

Supplemental disclosures of cash flow information:

               

Cash paid for interest

  $ 2,262,000     $ 2,094,000  

Supplemental non-cash financing and investing information:

               

Recording of beneficial conversion feature on debt

  $ --     $ 4,981,000  

Related party promissory note converted to common stock

  $ --     $ 3,000,000  

Convertible promissory note converted to common stock

  $ --     $ 369,000  
Transfer of inventory to fixed assets   $ 181,000     $ --  

 

See accompanying notes.

 

 

ThermoGenesis Holdings, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

 

 

1.

DESCRIPTION OF BUSINESS AND BASIS OF PRESENTATION

 

Description of Business

ThermoGenesis Holdings, Inc. (“ThermoGenesis Holdings,” the “Company,” “we,” “our,” “us”), develops, commercializes and markets a range of automated technologies for chimeric antigen receptor therapies (“CAR-T”) and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA.

 

The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for bio-manufacturing for immuno-oncology applications. The Company and its subsidiaries currently manufacture and market the following products:

 

Clinical Bio-Banking Applications:

 

AXP® II Automated Cell Separation System – an automated, fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood, registered as a U.S. FDA 510(k) medical device.

 

BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510(k) medical device.

 

Point-of-Care Applications:

 

PXP® Point-of-Care System – an automated, fully closed, sterile system allows for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics, registered as a U.S. FDA 510(k) medical device.

 

PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510(k) medical device.

 

PXP-1000 System – an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination, registered as a U.S. FDA 510(k) medical device.

 

Large Scale Cell Processing and Biomanufacturing:

 

X-Series® Products: X-Lab® for cell isolation, X-Wash® System for cell washing and reformulation, X-Mini® for high efficiency small scale cell purification, and X-BACS® System under development for large scale cell purification using our proprietary buoyancy-activated cell sorting (“BACS”) technology.

 

CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing CAR-T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% of the equity interest.

 

 

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such Securities and Exchange Commission (SEC) rules and regulations and accounting principles applicable for interim periods. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Events subsequent to the balance sheet date have been evaluated for inclusion in the accompanying condensed consolidated financial statements through the date of issuance.

 

Operating results for the three-month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the year ending December 31, 2021. These unaudited condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and the notes thereto included in ThermoGenesis Holdings, Inc. Annual Report on Form 10-K for the year ended December 31, 2020.

 

Principles of Consolidation

The consolidated financial statements include the accounts of ThermoGenesis Holdings, Inc. and its wholly-owned subsidiaries, ThermoGenesis Corp. and TotipotentRX Cell Therapy, Pvt. Ltd and ThermoGenesis Corp’s majority-owned subsidiary, CARTXpress Bio. All significant intercompany accounts and transactions have been eliminated upon consolidation.

 

The 20% ownership interest of CARTXpress Bio that is not owned by ThermoGenesis Holdings is accounted for as a non-controlling interest as the Company has an 80% ownership interest in CARTXpress Bio. Earnings or losses attributable to other stockholders of a consolidated affiliated company are classified separately as "non-controlling interest" in the Company's consolidated statements of operations. Net loss attributable to non-controlling interests reflects only its share of the after-tax earnings or losses of an affiliated company. The Company's condensed consolidated balance sheets reflect non-controlling interests within the equity section.

 

2.

GOING CONCERN

 

At September 30, 2021, the Company had cash and cash equivalents of $7,634,000 and working capital of $2,146,000.  The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future.  The Company may need to raise additional capital to grow its business, fund operating expenses and make interest payments.  The Company’s ability to fund its liquidity needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through debt borrowings, sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to the Company, if at all.  These factors and other indicators raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing date of this report.

 

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern.  The condensed consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

 

 

3.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

There have been no material changes in the Company’s significant accounting policies to those disclosed in the Company’s Annual Report filed on its Form 10-K for the year ended December 31, 2020.

 

Recently Adopted Accounting Standards

In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12Income Taxes (Topic 740): Simplifying the Accounting of Income Taxes”, which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years and interim periods within those fiscal years, beginning after December 15, 2020. The Company was not profitable for the nine months ended September 30, 2021 and has a full valuation allowance on all net operating loss (“NOL”) tax carryforwards. As such, the adoption of this standard did not have a material impact on the Company’s financial statements.

 

In January 2020, the FASB issued ASU 2020-01,Investments Equity Securities (Topic 321), InvestmentsEquity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815”. The new guidance clarifies the interaction of accounting for the transition into and out of the equity method and the accounting for measuring certain purchased options and forward contracts to acquire investments. It is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The adoption of this standard did not have a material impact on the Company’s financial statements.

 

Revenue Recognition

Revenue is recognized based on the five-step process outlined in Accounting Standards Codification (“ASC”) 606.

 

The following tables summarize the revenues by product line:

 

   

Three Months Ended September 30, 2021

 
   

Device

Revenue

   

Service

Revenue

   

Other

Revenue

   

Total

Revenue

 

AXP

  $ 2,217,000     $ 72,000     $ 21,000     $ 2,310,000  

BioArchive

    221,000       297,000       --       518,000  

CAR-TXpress

    160,000       31,000       71,000       262,000  

Manual Disposables

    55,000       --       --       55,000  

Other

    9,000       --       4,000       13,000  

Total

  $ 2,662,000     $ 400,000     $ 96,000     $ 3,158,000  

 

   

Nine Months Ended September 30, 2021

 
   

Device

Revenue

   

Service

Revenue

   

Other

Revenue

   

Total

Revenue

 

AXP

  $ 3,490,000     $ 159,000     $ 1,000     $ 3,670,000  

BioArchive

    652,000       1,165,000       --       1,817,000  

CAR-TXpress

    702,000       89,000       214,000       1,005,000  

Manual Disposables

    300,000       --       --       300,000  

Other

    46,000       --       38,000       84,000  

Total

  $ 5,190,000     $ 1,413,000     $ 273,000     $ 6,876,000  

 

 
   

Three Months Ended September 30, 2020

 
   

Device

Revenue

   

Service

Revenue

   

Other

Revenue

   

Total

Revenue

 

AXP

  $ 1,137,000     $ 32,000     $ --     $ 1,169,000  

BioArchive

    337,000       282,000       --       619,000  

CAR-TXpress

    332,000       22,000       71,000       425,000  

Manual Disposables

    100,000       --       --       100,000  

Other

    26,000       --       16,000       42,000  

Total

  $ 1,932,000     $ 336,000     $ 87,000     $ 2,355,000  

 

   

Nine Months Ended September 30, 2020

 
   

Device

Revenue

   

Service

Revenue

   

Other

Revenue

   

Total

Revenue

 

AXP

  $ 4,009,000     $ 103,000     $ --     $ 4,112,000  

BioArchive

    675,000       900,000       --       1,575,000  

CAR-TXpress

    1,035,000       47,000       214,000       1,296,000  

Manual Disposables

    499,000       --       --       499,000  

Other

    276,000       --       39,000       315,000  

Total

  $ 6,494,000     $ 1,050,000     $ 253,000     $ 7,797,000  

 

Contract Balances

Generally, all sales are contract sales (with either an underlying contract or purchase order).  The Company does not have any material contract assets.  When invoicing occurs prior to revenue recognition, a contract liability is recorded (as deferred revenue on the balance sheet).  Revenues recognized during the three and nine months ended September 30, 2021 that were included in the beginning balance of deferred revenue were $118,000 and $521,000, respectively.  Short-term deferred revenues increased from $608,000 to $943,000 and long-term deferred revenues decreased from $1,596,000 to $1,395,000 during the nine months ended September 30, 2021, respectively.

 

Exclusivity Fee

On August 30, 2019, the Company entered into a Supply Agreement with Corning Incorporated (the “Supply Agreement”).  The Supply Agreement has an initial term of five years with Corning having two options to renew for an additional two-years (up to four years total), unless terminated by either party in accordance with the terms of the Supply Agreement (collectively, the “Term”). Pursuant to the Supply Agreement, the Company has granted Corning exclusive worldwide distribution rights for substantially all X-Series® products under the CAR-TXpress™ platform (the “Products”) manufactured by its subsidiary, ThermoGenesis Corp., for the duration of the Term, subject to certain geographical and other exceptions. In addition to any amounts payable throughout the Term for the Products, as consideration for the exclusive worldwide distribution rights for the Products, Corning paid a $2,000,000 exclusivity fee.  For the three and nine months ended September 30, 2021 and 2020, the Company recorded revenue related to the exclusivity fee of $71,000 and $214,000, respectively.  The remaining balance of the $2,000,000 payment of $1,405,000 is recorded as deferred revenue, with $286,000 in short-term deferred revenue and $1,119,000 recorded in long-term deferred revenue.

 

Distribution Agreement

The Company signed a new agreement with its AXP distributor in China through 2023.  The new agreement called for the distributor to purchase a minimum of $1,400,000 of AXP disposables in 2021, then $650,000 in each of the next two years.  In return for the minimum purchase commitment, the Company is providing the distributor with AXP processing devices to use during the term of the agreement.  The Company maintains ownership of these devices and they must be returned to the Company at the end of the agreement in 2024.  The Company analyzed the relevant accounting guidance and determined that the equipment and AXP bagsets represented distinct performance obligations. The equipment was concluded to be an embedded lease, accounted for as a sales-type operating lease.  At September 30, 2021, the value of those assets was approximately $180,000 and they will be amortized over their accounting estimated useful life of five years.  A portion of the revenue from each bagset shipment will be allocated and recorded as deferred revenue to be recognized as lease revenue over the term of the agreement.  The expected lease revenue is $21,000 per quarter.  At September 30, 2021, the Company had $82,000 in short term and $27,000 in long term deferred revenue related to future lease revenue.

 

 

Backlog of Remaining Customer Performance Obligations

The following table includes revenue expected to be recognized and recorded as sales in the future from the backlog of performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

 

   

Remainder

of 2021

   

2022

   

2023

   

2024

   

2025 and

beyond

   

Total

 

Service revenue

  $ 359,000     $ 962,000     $ 462,000     $ 189,000     $ 85,000     $ 2,057,000  

Clinical revenue

    3,000       13,000       13,000       13,000       160,000       202,000  

Device revenue(1)

    21,000       674,000       674,000       41,000       --       1,410,000  

Exclusivity fee

    72,000       286,000       286,000       286,000       476,000       1,406,000  

Total

  $ 455,000     $ 1,935,000     $ 1,435,000     $ 529,000     $ 721,000     $ 5,075,000  

 

 

(1)

Represents the minimum purchase requirements related to the Company AXP distributor in China

 

Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.

 

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation. The reclassifications did not have an impact on net loss as previously reported. For the three and nine month periods ended September 30, 2021, sales and marketing and general and administrative expenses were combined into one line item identified as sales, general and administrative expenses on the Statement of Operations. Additionally, the loss on equity method investments was combined with other income on the Statement of Operations.

 

 

4.

NET LOSS PER SHARE

 

Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding plus the pre-funded warrants. For the purpose of calculating basic net loss per share, the additional shares of common stock that are issuable upon exercise of the pre-funded warrants have been included since the shares are issuable for a negligible consideration and have no vesting or other contingencies associated with them. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents noted below is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at September 30:

 

   

2021

   

2020

 

Common stock equivalents of convertible promissory notes and accrued interest

    7,071,241       6,988,334  

Vested Series A warrants

    --       40,441  

Unvested Series A warrants(1)

    --       69,853  

Warrants – other

    653,248       1,006,190  

Stock options

    366,595       892,149  

Total

    8,091,084       8,996,967  

 


 

(1)

The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants remained outstanding but unvested until they expired in February 2021.

 

 

 

5.

RELATED PARTY TRANSACTIONS

 

HealthBanks Biotech (USA) Inc.

On November 26, 2019 the Company entered into an agreement with HealthBanks Biotech (USA) Inc. (“HealthBanks”) to form a new company called ImmuneCyte, Inc. (“ImmuneCyte”) to commercialize the Company’s proprietary cell processing platform, CAR-TXpress™, for use in immune cell banking as well as for cell-based contract development and manufacturing services (CMO/CDMO). Under the terms of the agreement, ImmuneCyte was initially owned 80% by HealthBanks and 20% by the Company. Healthbanks is a subsidiary of the Boyalife Group (USA), Inc. which is owned by Dr. Xiaochun (Chris) Xu, the Company’s Chief Executive Officer and Chairman of our Board of Directors. Due to the significant influence the Company has over ImmuneCyte’s operations, the investment was accounted for by the Company using the equity method.

 

Between November 26, 2019 and September 30, 2020, ImmuneCyte closed on a series of investments with a private institution and qualified investors. After the investments, ImmuneCyte was owned 75.16% by HealthBanks, 18.79% by the Company and 6.05% by the private investors.

 

In March 2021, ImmuneCyte completed an acquisition to acquire Boyalife’s Cellular Therapy Division, for 12,000,000 shares in ImmuneCyte and Shangai KDWinfo Technology Co. Ltd. For 500,000 shares in ImmuneCyte.  Following the acquisitions, the Company’s ownership percentage in ImmuneCyte decreased from 18.79% to 8.64%.  The Company performed an analysis of the transaction and noted that none of the factors supporting significant influence changed as a result of the acquisition.  Therefore, it was concluded that significant influence remains and the Company will continue to account for the transaction using the equity method.  The Company recognized a dilution gain of $262,000 representing its share of the net assets acquired by ImmuneCyte.  However, at the time of the acquisition, the Company had accumulated losses of $428,000 in its investment in ImmuneCyte.  As the accumulated losses were greater than the dilution gain, no entry was recorded by the Company for its investment in ImmuneCyte for the quarter ended March 31, 2021.

 

As of September 30, 2021, the value of the Company’s investment in ImmuneCyte on its Balance Sheet is $0. For the quarter ended September 30, 2021, ImmuneCyte had a consolidated net loss of $750,000; its current assets were $3,283,000 and current liabilities were $2,970,000.

 

Convertible Promissory Note and Revolving Credit Agreement

In March 2017, ThermoGenesis Holdings entered into a Credit Agreement with Boyalife Asset Holding II, Inc. (the “Lender”). The Lender is a wholly owned subsidiary of the Boyalife Group (USA), Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors. The Credit Agreement, as amended, grants to the Company the right to borrow up to $10,000,000 (the “Loan”) at any time prior to March 6, 2022 (the “Maturity Date”). As of September 30, 2021 and December 31, 2020, the Company had an outstanding principal balance on the Loan of $10,000,000.

 

The Credit Agreement and the Convertible Promissory Note issued thereunder (as amended, the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% per annum, simple interest. The Company has five business days after the Lender demands payment to pay the interest due before the Loan is considered in default. In January 2021, the Company paid the Lender, the interest due as of December 31, 2020 in the amount of $2,082,000. The Note can be prepaid in whole or in part by the Company at any time without penalty.

 

 

The Credit Agreement and Note were amended in April 2018, granting the Lender the right to convert, at any time, outstanding principal and accrued but unpaid interest into shares of the Company’s common stock at a conversion price of $16.10 per share. The amendment included a down-round provision that lowered the conversion price if the Company issues shares of common stock at a lower price per share, the conversion price of the Note is lowered to that amount. The Company completed a transaction in 2018, which lowered the conversion price to $1.80.

 

The following summarizes the Note:

 

 

Maturity

Date

 

Stated

Interest

Rate

   

Conversion

Price

   

Face Value

   

Remaining

Debt

Discount

   

Carrying

Value

 

At September 30, 2021

3/6/2022

    22%       $1.80       $10,000,000       $(1,583,000)       $8,417,000  

At December 31, 2020

3/6/2022

    22%       $1.80       $10,000,000       $(4,065,000)       $5,935,000  

 

The Company amortized $827,000 and $2,482,000 of debt discount to interest expense for the three and nine months ended September 30, 2021 and $827,000 and $2,103,000 for the three and nine months ended September 30 2020, respectively. In addition to the amortization, the Company also recorded interest expense of $562,000 and $1,668,000 for the three and nine months ended September 30, 2021 and $562,000 and $1,519,000 for the three and nine months ended September 30 2020, respectively. The interest payable balance as of September 30, 2021 and December 31, 2020 was $1,668,000 and $2,082,000, respectively.

 

6.

CONVERTIBLE PROMISSORY NOTE

 

July 2019 Note

On July 23, 2019, the Company entered into a private placement with the Accredited Investor, pursuant to which the Company issued and sold to such investor an unsecured convertible promissory note in the original principal amount of $1,000,000 (the “July 2019 Note”). The July 2019 Note is convertible into shares of the Company's common stock at a conversion price equal to the lower of (a) $1.80 per share or (b) 90% of the closing sale price of the Company’s common stock on the date of conversion (subject to a floor conversion price of $0.50). The July 2019 Note bears interest at the rate of twenty-four percent (24%) per annum and is payable quarterly in arrears. Unless sooner converted in the manner described below, all principal under the July 2019 Note, together with all accrued and unpaid interest thereupon, will be due and payable three years from the date of the issuance on July 31, 2022.

 

The following summarizes the July 2019 Note:

 

 

Maturity

Date

 

Stated

Interest

Rate

   

Conversion

Price

   

Face Value

   

Remaining

Debt

Discount

   

Carrying

Value

 

At September 30, 2021

7/31/2022

    24%       $1.80       $1,000,000       $(267,000)       $733,000  

At December 31, 2020

7/31/2022

    24%       $1.80       $1,000,000       $(507,000)       $493,000  

 

The Company recorded amortization expense for the debt discount on the July 2019 Note for the three and nine months ended September 30, 2021 of $80,000 and $241,000, respectively; and $27,000 and $107,000 for the three and nine months ended September 30, 2020. Interest expense related to the July 2019 Note was $60,000 and $180,000 for the three and nine months ended September 30, 2021 and 2020.

 

 

7.

LEASES

 

The Company leases an approximately 28,000 square foot facility located in Rancho Cordova, California for its corporate offices and in-house manufacturing. The lease was renewed in the first quarter of 2019 and is accounted for as an operating lease. The lease expires in May 2024.

 

Operating Leases

Operating lease assets and liabilities are recognized at the lease commencement date. Operating lease liabilities represent the present value of lease payments not yet paid. Operating lease assets represent our right to use an underlying asset and are based upon the operating lease liabilities adjusted for prepayments or accrued lease payments, initial direct costs, lease incentives, and impairment of operating lease assets. To determine the present value of lease payments not yet paid, we use the Company’s cost of capital based on existing debt instruments. Our material leases typically contain rent escalations over the lease term. We recognize expense for these leases on a straight-line basis over the lease term.

 

The following summarizes the Company’s operating leases:

 

   

September 30,

2021

   

December 31,

2020

 

Right-of-use operating lease assets, net

  $ 614,000     $ 730,000  

Current lease liability (included in other current liabilities)

    193,000       157,000  

Non-current lease liability

    455,000       604,000  
                 

Weighted average remaining lease term

    2.7       3.4  

Discount rate

    22 %     22 %

 

Maturities of lease liabilities by year for our operating leases are as follows:

 

2021 (Remaining)

  $ 78,000  

2022

    319,000  

2023

    328,000  

2024

    139,000  

Total lease payments

  $ 864,000  

Less: imputed interest

    (217,000 )

Present value of operating lease liabilities

  $ 647,000  

 

Statement of Cash Flows

In January 2019, the Company signed an amendment to its Rancho Cordova, California lease. The amendment was accounted for as a modification and resulted in a right-of-use asset of $966,000 being recognized as a non-cash addition on the date of the amendment. Cash paid for amounts included in the measurement of operating lease liabilities included in cash flow from operating activities was $78,000 and $231,000 for the three and nine months ended September 30, 2021 and $76,000 and $225,000 for the three and nine months ended September 30, 2020, respectively.

 

 

Operating Lease Costs

Operating lease costs were $107,000 and $316,000 for the three and nine months ended September 30, 2021 and $135,000 and $343,000 for the three and nine months ended September 30, 2020, respectively. These costs are primarily related to long-term operating leases, but also include amounts for variable lease costs, as well as immaterial and short-term leases.

 

Finance Leases

Finance leases are included in equipment and other current and non-current liabilities on the condensed consolidated balance sheet. The amortization and interest expense are included in general and administrative expense and interest expense, respectively on the statement of operations. These leases were not material for the three and nine months ended September 30, 2021 and 2020.

 

8.

COMMITMENTS AND CONTINGENCIES

 

Contingencies

In the normal course of operations, the Company may have disagreements or disputes with customers, employees or vendors. Such potential disputes are seen by management as a normal part of business. As of September 30, 2021, except as disclosed, management believes any liability that may ultimately result from the resolution of these matters will not have a material adverse effect on the Company’s condensed consolidated financial position, operating results or cash flows.

 

Financial Covenants

On July 13, 2020, the Company, entered into a Manufacturing and Supply Amending Agreement #2 with CBR Systems, Inc. (“CBR”) with an effective date of July 13, 2020 (the “Amendment”). The Amendment amends the Manufacturing and Supply Agreement entered into on May 15, 2017 and Amendment #1 dated March 16, 2020 by the Company and CBR. The Amendment, among other things, revised the amount of certain products to be purchased, pricing of those products and removal of the safety stock requirement. In addition, the Amendment updated the financial requirement to exclude convertible debt from the definition of short-term debt under events or conditions that constitute a default. The Amendment states that the Company’s cash balance and short-term investments net of non-convertible debt and borrowed funds that are payable within one year must be greater than $1,000,000 at any month end. The Company was in compliance with this agreement as of September 30, 2021.

 

Warranty

The Company offers a warranty on all of its non-disposable products of one to two years. The Company warrants disposable products through their expiration date. The Company periodically assesses the adequacy of its recorded warranty liabilities and adjusts the amounts as necessary.

 

The warranty liability is included in other current liabilities in the unaudited condensed consolidated balance sheets. The change in the warranty liability for the nine months ended September 30, 2021 is summarized in the following table:

 

 

Balance at December 31, 2020

  $ 154,000  

Warranties issued during the period

    53,000  

Settlements made during the period

    (140,000 )

Changes in liability for pre-existing warranties during the period

    --  

Balance at September 30, 2021

  $ 67,000  

 

 

9.

PAYCHECK PROTECTION PROGRAM

 

On April 21, 2020, the Company entered into a promissory note and received a Paycheck Protection Program loan “PPP Loan” from the Small Business Association “SBA”, which was established under the CARES Act. The Company received net proceeds of $646,000 from the PPP Loan. The term of the PPP Loan is two years with an interest rate of 1.00% per annum, which was deferred for the first six months of the term of the loan or after an application is filed for loan forgiveness, whichever is later. Each monthly payment shall be in the amount which would fully amortize the principal balance outstanding under the PPP Loan. Pursuant to the terms of the CARES Act, the proceeds of the PPP Loan may be used for payroll costs, mortgage interest, rent or utility costs. The promissory note of the PPP Loan contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, or provisions of the promissory note. The occurrence of an event of default may result in a claim for the immediate repayment of the amount outstanding under the PPP Loan. In late December 2020, the Company applied with the SBA for forgiveness of the PPP Loan and was notified on March 30, 2021 that the SBA had approved our application to forgive the entire amount of the loan and accrued interest. For the nine months ended September 30, 2021, the Company recorded a gain on extinguishment of debt of $652,000 representing the principal and accrued interest for the PPP Loan at the time of forgiveness.

 

10.

EMPLOYEE RETENTION TAX CREDIT

 

Employee Retention Tax Credits (“ERTC”), created in the  March 2020 CARES Act and then subsequently amended by the Consolidated Appropriation Act (“CAA”) of 2021 and the American Rescue Plan Act (“ARPA”) of 2021, is a refundable payroll credit for qualifying businesses keeping employees on their payroll during the COVID-19 pandemic.  Under CAA and ARPA amendments, employers can claim a refundable tax credit against the employer share of social security tax equal to 70% of the qualified wages (including certain health care expenses) paid to employees from January 1, 2021 to  December 31, 2021.  Qualified wages are limited to $10,000 per employee per quarter in 2021 so the maximum ERTC available is $7,000 per employee per quarter. 

 

The Company is eligible to receive the ERTC credits under the gross receipts decline test when comparing the first, second and third quarters of 2021 to the same quarters in 2019, which qualified the Company to claim ERTC the first three quarters of 2021 under the amended ERTC program. The Company qualified for a refundable payroll tax credit totaling $842,000 for the first three quarters of 2021, which is recorded in other income on the Company’s consolidated statement of operations for the three and nine months ended  September 30, 2021, and prepaid and other current assets on the Company’s consolidated balance sheet as of  September 30, 2021.

 

11.

STOCKHOLDERS EQUITY

 

Common Stock

On December 13, 2019, the Company entered into an At The Market Offering Agreement, by and between the Company and H.C. Wainwright & Co., LLC, as agent (“H.C. Wainwright”) (the “ATM Agreement”), pursuant to which the Company may offer and sell, from time to time through H.C. Wainwright, shares of the Company’s common stock, having an aggregate offering price of up to $4,400,000 and on May 19, 2020 the ATM Agreement was amended to increase the aggregate value of up to $15,280,313 (the “HCW Shares”). As of September 30, 2021, the Company sold a total of 5,597,484 shares of the Company’s common stock for aggregate gross proceeds of $15,280,000 at an average selling price of $2.73 per share, resulting in net proceeds of approximately $14,568,000 after deducting legal expenses, audit fees, commissions and other transaction costs of approximately $712,000. For the nine months ended September 30, 2021, the Company sold 2,976,832 shares of common stock for net proceeds of $6,832,000 after deducting $224,000 in commissions and other transaction costs.

 

 

Stock Based Compensation

 

In May 2021, five Company executives voluntarily surrendered the options they were awarded in June 2020. At the time they were surrendered, the exercise price of the options was underwater. No payment or other consideration was paid to the Company executives for surrendering the options. In total 490,000 options were cancelled. As a result of the cancellation, the remaining unamortized expense of $2,008,000 was accelerated and recorded in the three months ended June 30, 2021.

 

The Company recorded stock-based compensation of $92,000 and $2,449,000 for the three and nine months ended September 30, 2021, and $234,000 and $615,000 for the three and nine months ended September 30, 2020, respectively, as comprised of the following:

 

   

Three Months Ended

September 30,

   

Nine Months Ended

September 30,

 
   

2021

   

2020

   

2021

   

2020

 

Cost of revenues

  $ 4,000     $ 3,000     $ 14,000     $ 5,000  

Selling, general and administrative

    64,000       195,000       2,194,000       538,000  

Research and development

    24,000       36,000       241,000       72,000  
    $ 92,000     $ 234,000     $ 2,449,000     $ 615,000  

 

The following is a summary of option activity for the Company’s stock option plans:

 

   

Number of

Shares

   

Weighted-

Average

Exercise

Price

   

Weighted-

Average

Remaining

Contractual

Life

   

Aggregate

Intrinsic

Value

 

Outstanding at December 31, 2020

    889,636     $ 8.57       8.7     $ --  
                                 

Cancelled / Forfeited

    523,041                          
                                 

Outstanding at September 30, 2021

    366,595     $ 11.86       7.1     $ --  
                                 

Vested and expected to vest at September 30, 2021

    331,128     $ 12.36       6.9     $ --  
                                 

Exercisable at September 30, 2021

    244,245     $ 13.97       7.0     $ --  

 

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no options exercised during the nine months ended September 30, 2021.

 

 

Warrants

A summary of warrant activity for the nine months ended September 30, 2021 is as follows:

 

   

Number of

Shares

   

Weighted-Average

Exercise Price Per

Share

   

Weighted-

Average

Remaining

Contract Term

 

Balance at December 31, 2020

    1,116,484     $ 37.27       0.49  

Warrants expired

    463,236                  

Warrants exercised

    --     $ --          

Outstanding at September 30, 2021

    653,248     $ 6.97       1.70  

Exercisable at September 30, 2021

    653,248     $ 6.97       1.70  
 

12.

MAJOR CUSTOMERS AND ACCOUNTS RECEIVABLE

 

The Company had certain customers whose revenue individually represented 10% or more of the Company’s total revenue, or whose accounts receivable balances individually represented 10% or more of the Company’s total accounts receivable as follows:

 

For net revenues, one customer accounted for 42% and 20%, a second customer accounted for 24% and 22% and a third customer accounted for 0% and 10% for the three months ended September 30, 2021 and 2020, respectively.  For the nine months ended September 30, 2021 and 2020, one customer accounted for 19% and 12%, a second customer accounted for 17% and 27%, while a third customer accounted for 10% and 12% of net revenues, respectively.

 

At September 30, 2021, two customers accounted for 67% of accounts receivable. At December 31, 2020, three customers accounted for 72% of accounts receivable.

 

ITEM 2. Managements Discussion and Analysis of Financial Condition and Results of Operations

 

Cautionary Note Regarding ForwardLooking Statements

This report contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements contained herein. When used in this report, the words "anticipate," "believe," "estimate," "expect" and similar expressions as they relate to the Company or its management are intended to identify such forward-looking statements. Actual results, performance or achievements could differ materially from the results expressed in, or implied by these forward-looking statements. Readers should be aware of important factors that, in some cases, have affected, and in the future could affect, actual results to differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. These factors include without limitation, the ability to obtain capital and other financing in the amounts and at the times needed to launch new products, market acceptance of new products, the nature and timing of regulatory approvals for both new products and existing products for which the Company proposes new claims, realization of forecasted revenues, expenses and income, initiatives by competitors, price pressures, failure to meet U.S. Food and Drug Administration (“FDA”) regulated requirements governing the Company’s products and operations (including the potential for product recalls associated with such regulations), risks associated with initiating manufacturing for new products, failure to meet Foreign Corrupt Practice Act regulations, legal proceedings, uncertainty associated with the COVID-19 pandemic, and other risk factors listed from time to time in our reports with the Securities and Exchange Commission (“SEC”), including, in particular, those set forth in The Company’s Form 10-K for the year ended December 31, 2020.

 

 

Business Overview

ThermoGenesis Holdings, Inc. develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The Company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress™ platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. The Company was founded in 1986 and is incorporated in the State of Delaware and headquartered in Rancho Cordova, CA.

 

The Company provides the AutoXpress® and BioArchive® platforms for automated clinical bio-banking, PXP® platform for point-of-care cell-based therapies and CAR-TXpress™ platform for bio-manufacturing for immuno-oncology applications. The Company and its subsidiaries currently manufacture and market the following products:

 

Clinical Bio-Banking Applications:

 

AXP® II Automated Cell Separation System – an automated, fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood, registered as a U.S. FDA 510(k) medical device.

 

BioArchive® Automated Cryopreservation System – an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications, registered as a U.S. FDA 510(k) medical device.

 

Point-of-Care Applications:

 

PXP® Point-of-Care System – an automated, fully closed, sterile system allows for the rapid, automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics, registered as a U.S. FDA 510(k) medical device.

 

PXP-LAVARE System – an automated, fully closed system that is designed to wash, re-suspend and volume reduce cell suspensions. It allows for volume manipulation, supernatant or media exchange, and cell washing to occur without comprising cell viabilities and maximizing recoveries, registered as a U.S. FDA 510(k) medical device.

 

PXP-1000 System – an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination, registered as a U.S. FDA 510(k) medical device.

 

Large Scale Cell Processing and Biomanufacturing:

 

X-Series® Products: X-Lab® for cell isolation, X-Wash® System for cell washing and reformulation, X-Mini® for high efficiency small scale cell purification, and X-BACS® System under development for large scale cell purification using our proprietary buoyancy-activated cell sorting (“BACS”) technology.

 

CAR-TXpress™ Platform – a modular designed, functionally closed platform that addresses the critical unmet need for large scale cellular processing and chemistry, manufacturing and controls (“CMC”) needs for manufacturing CAR-T cell therapies. The CAR-TXpress Platform is owned and developed through a subsidiary CAR-TXpress Bio, Inc. (“CARTXpress Bio”) in which the Company owns 80% of the equity interest.

 

 

ThermoGenesis Holdings is an affiliate of the Boyalife Group, a global diversified life science holding company that focuses on stem cell technology and cell-based therapeutics.

 

COVID-19

We believe that the COVID-19 pandemic has had a material negative impact on the Company’s business and results of operations. The pandemic had a significant impact on the cord blood industry, with fewer cord blood units being stored globally after the start of the pandemic. The continued impact of the pandemic on the Company’s business and results of operations will depend on future developments relating to the pandemic in general and the cord blood industry in particular, and such future developments are highly uncertain and cannot be predicted. Such developments may include the continued geographic spread of the virus, the severity of the disease, the duration of the outbreak, the actions that may be taken by various governmental authorities in response to the outbreak, and the possible continued impact on the U.S. or global economy and supply chains. As a result, at the time of this filing, it is impossible to predict the continued impact of the pandemic on the Company’s business, liquidity, capital resources and financial results.

 

 

Critical Accounting Policies

Management’s discussion and analysis of its financial condition and results of operations is based upon the condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires management to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosure of contingent assets and liabilities. Estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. For a full discussion of our accounting estimates and assumptions that have been identified as critical in the preparation of the Company’s condensed consolidated financial statements, please refer to ThermoGenesis Holdings’ Form 10-K for the year ended December 31, 2020.

 

 

Results of Operations for the Three Months Ended September 30, 2021 as Compared to the Three Months Ended September 30, 2020

 

The following tables summarizes revenues by product line:

 

   

Three Months Ended

September 30,

                 
   

2021

   

2020

   

$ Change

   

% Change

 

AXP

  $ 2,310,000     $ 1,169,000     $ 1,141,000       98 %

BioArchive

    518,000       619,000       (101,000 )     (16 )%

CAR-TXpress

    262,000       425,000       (163,000 )     (38 )%

Manual Disposables

    55,000       100,000       (45,000 )     (45 )%

Other

    13,000       42,000       (29,000 )     (69 )%

Total

  $ 3,158,000     $ 2,355,000     $ 803,000       34 %

 

 

Net Revenues

Net revenues increased by $803,000 or 34%, from $2,355,000 to $3,158,000 for the three months ended September 30, 2021 as compared to the three months ended September 30, 2020.  The increase was primarily driven by AXP sales, which increased by $1,141,000 or 98% in the three months ended September 30, 2021 as compared to the same period in 2020.  The increased AXP revenue related to the new three year contract the Company signed with its distributor in China.  The contract called for the distributor to purchase approximately three containers of AXP bagsets in 2021, representing approximately $1,400,000 in revenue.  Those containers were shipped in the third quarter of 2021.  This resulted increased revenue of approximately $1,000,000 in the third quarter of 2021 related to the Company’s distributor in China as compared to the same period in 2020, as they only purchased approximately $450,000 of AXP bagsets in the three months ended September 30, 2020.  The remainder of the increase relates to domestic AXP bagset sales, which increased by approximately 100 cases or $200,000 in the three months ended September 30, 2021 as compared to the same period in 2020.  Revenues in the Company’s other product lines decreased by a combined $338,000.  The largest decrease is related to CAR-TXpress sales.  The Company sells this product line primarily through its exclusive worldwide distributor for x-series products, Corning Incorporated.  They have indicated that the COVID-19 pandemic is still hindering their ability to expand revenue for the product line, as they are unable to on site demos and other sales activities that occurred prior to the start of the pandemic.

 

Gross Profit

The Company’s gross profit was $1,115,000 or 35% of net revenues for the three months ended September 30, 2021, compared to $1,511,000 or 64% of net revenues for the three months ended September 30, 2020, a decrease of $396,000 or 26%.  The decrease was driven by a refund of $800,000 received in the three months ended September 30, 2020 from ImmuneCyte relating to COVID-19 testing kits which were previously reserved by the Company in a prior quarter.  The decrease was offset by higher gross profit from AXP disposables of approximately $400,000 generated by the increased sales of AXP disposables in the three months ended September 30, 2021.

 

Selling, General and Administrative

Sales, general and administrative expenses for the three months ended September 30, 2021 were $1,677,000 compared to $1,844,000 for the three months ended September 30, 2020, a decrease of $167,000 or 9%. The decrease was driven by lower personnel expenses which decreased by approximately $225,000, and lower stock compensation expense, which decreased by approximately $130,000, in the three months ended September 30, 2021 as compared to the same period in 2020.  These decreases were offset by increased consulting expenses of approximately $200,000.

 

Research and Development Expenses

Research and development expenses were $543,000 for the three months ended September 30, 2021 as compared to $750,000 for the three months ended September 30, 2020, a decrease of $207,000 or 28%. The decrease was driven by development expenses for the Company’s COVID-19 cartridge reader of approximately $150,000 incurred in the three months ended September 30, 2020 and lower stock compensation expense of approximately $50,000 in the three months ended September 30, 2021.

 

Interest Expense

Interest expense for the three months ended September 30, 2021 was $1,530,000, compared to $1,531,000 for the three months ended September 30, 2020, a decrease of $1,000. Interest expense was essentially flat year over year due the interest expense and amortization of the debt discount related to the Revolving Credit Agreement with Boyalife Asset Holding II, Inc. being the same in both periods.

 

 

Results of Operations for the Nine Months Ended September 30, 2021 as Compared to the Nine Months Ended September 30, 2020

 

The following tables summarizes revenues by product line:

 

   

Nine Months Ended

September 30,

                 
   

2021

   

2020

   

$ Change

   

% Change

 

AXP

  $ 3,670,000     $ 4,112,000       (442,000 )     (11 )%

BioArchive

    1,817,000       1,575,000       242,000       15 %

CAR-TXpress

    1,005,000       1,296,000       (291,000 )     (22 )%

Manual Disposales

    300,000       499,000       (199,000 )     (40 )%

Other

    84,000       315,000       (231,000 )     (73 )%

Total

  $ 6,876,000     $ 7,797,000     $ (921,000 )     (12 )%

 

Net Revenues

Net revenues decreased by $921,000 or 12%, from $7,797,000 to $6,876,000 for the nine months ended September 30, 2021 as compared to the nine months ended September 30, 2020. The decrease was driven by lower AXP® disposable sales which declined by approximately $350,000 with 100 fewer cases sold in the nine months ended September 30, 2021 as compared to the same period in 2020. Additionally, there were decreases in the CAR-TXpress and manual disposable product lines of $291,000 and $199,000, respectively, primarily as a result of the COVID-19 pandemic. Other revenues also decreased by $231,000 due to COVID-19 testing kits of which the Company didn’t sell in the nine months ended September 30, 2021. Offsetting the decreases, was an increase in BioArchive service revenue of $265,000 in the nine months ended September 30, 2021, as compared to the same period in 2020.

 

Gross Profit

The Company’s gross profit was $2,809,000 or 41% of net revenues for the nine months ended September 30, 2021, compared to $371,000 or 5% for the nine months ended September 30, 2020, an increase of $2,438,000. The current year gross profit is consistent with the Company’s standard profit margins. The gross profit was lower in the prior year due to increased inventory reserve expenses of approximately $2,800,000. The inventory reserve expense recognized in 2020 was primarily for COVID-19 testing kits, which are no longer being sold by the Company. Offsetting the increase was a decrease in gross profit provided by AXP disposables of approximately $300,000.

 

Selling, General and Administrative

Selling, general and administrative expenses for the nine months ended September 30, 2021 were $7,171,000 compared to $5,913,000 for the nine months ended September 30, 2020, an increase of $1,258,000 or 21%. The increase was driven by stock compensation expense, which increased by approximately $1,700,000 primarily due to the accelerated expense for the stock options that were voluntarily surrendered by Company executives and increased consulting expenses of approximately $200,000 in the nine months ended September 30, 2021.  The increase is offset by a decrease of approximately $325,000 in lower legal expenses primarily due to the absence of expenses related to the Mavericks lawsuit incurred in the prior year, approximately $100,000 less in fixed asset impairment expense, approximately $125,000 less in patent expense and approximately $60,000 less in investor relations related expenses in the nine months ended September 30, 2021 as compared to the same period in 2020.

 

 

Research and Development Expenses

Consolidated research and development expenses were $1,544,000 for the nine months ended September 30, 2021, compared to $1,937,000 for the nine months ended September 30, 2020, a decrease of $393,000 or 20%. The decrease was driven by lower salaries and benefits of approximately $550,000 offset by increased stock compensation expense of approximately $175,000 in the nine months ended September 30, 2021 as compared to the same period in 2020.

 

Interest Expense

Interest expense decreased to $4,573,000 for the nine months ended September 30, 2021 as compared to $6,377,000 for the nine months ended September 30, 2020, a decrease of $1,804,000. The decrease is driven an accelerated expense of $2,486,000 for the unamortized debt discount of the beneficial conversion feature associated with the portions of the Revolving Credit Agreement with Boyalife Asset Holding II, Inc. which were converted in the nine months ended September 30, 2020. This decrease was offset by additional interest expense and debt discount amortization of approximately $500,000 related to additional draw down from the Revolving Credit Agreement with Boyalife Asset Holding II, Inc. that occurred in the second quarter of 2020.

 

Liquidity and Capital Resources

At September 30, 2021, the Company had cash and cash equivalents of $7,634,000 and working capital of $2,146,000. This compares to cash and cash equivalents of $7,161,000 and working capital of $9,155,000 at December 31, 2020. We have primarily financed operations through private and public placement of equity securities and our line of credit facility.

 

The Company has a Revolving Credit Agreement with Boyalife Asset Holding II, Inc. As of September 30, 2021, the Company had drawn down the full $10,000,000 that is available under the Revolving Credit Agreement, which matures in March of 2022. Boyalife Asset Holding II, Inc. is a wholly-owned subsidiary of Boyalife Group Inc. (USA), which is owned and controlled by the Company’s Chief Executive Officer and Chairman of our Board of Directors.

 

During 2020, the Company received a loan totalling net proceeds of $646,000 from the SBA under the Payment Protection Program of the CARES Act, in response to the COVID-19 pandemic described above. The CARES Act permits that a loan may be forgiven if certain criteria are met. In March 2021, the SBA approved the Company’s application to forgive the entire amount of the debt. In the nine months ended September 30, 2021, the Company recognized a gain of the forgiveness of debt for $652,000 representing the principal balance and accrued interest related to the loan at the time of forgiveness.

 

The Company has incurred historical losses from operations and expects to continue to incur operating losses in the near future. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year from the filing of this report. The Company may require additional capital to grow the business, to fund other operating expenses and to make interest payments. The Company’s ability to fund its cash needs is subject to various risks, many of which are beyond its control. The Company may seek additional funding through bank borrowings or public or private sales of debt or equity securities or strategic partnerships. The Company cannot guarantee that such funding will be available on a timely basis, in needed quantities or on terms favorable to us, if at all.

 

Non-GAAP Measures

In addition to the results reported in accordance with US GAAP, we also use a non-GAAP measure, adjusted EBITDA, to evaluate operating performance and to facilitate the comparison of our historical results and trends. The Company calculates adjusted EBITDA as income or (loss) from operations less depreciation, amortization, stock compensation, equity method investments and impairment of intangible assets. This financial measure is not a measure of financial performance under US GAAP and should not be considered in isolation or as a substitute for loss as a measure of performance. The calculation of this non-GAAP measure may not be comparable to similarly titled measures used by other companies. Reconciliations to the most directly comparable GAAP measure are provided below.

 

 

Three months ended September 30, 2021 and 2020, respectively:

 

   

Three Months Ended September 30,

 
   

2021

   

2020

 

Net loss

  $ (1,792,000 )   $ (2,609,000 )
                 

Deduct:

               

Interest expense

    (1,530,000 )     (1,531,000 )

Other expense

    843,000       5,000  

Loss from operations

  $ (1,105,000 )   $ (1,083,000 )
                 

Add:

               

Depreciation and amortization

    157,000       177,000  

Stock-based compensation expense

    92,000       234,000  

Adjusted EBITDA

  $ (856,000 )   $ (672,000 )

 

Adjusted EBITDA for the three months ended September 30, 2021 was a loss of $856,000, compared to a loss of $672,000 for the three months ended September 30, 2020, a decrease of $184,000. The adjusted EBITDA decrease was primarily due to $287,000 less in gross profit and $200,000 more in consulting fees incurred in the three months ended September 30, 2021 as compared to the same period in 2020. These decreasing items were offset by approximately $225,000 less in selling, general and administrative personnel expenses.

 

Nine months ended September 30, 2021 and 2020, respectively:

 

   

Nine Months Ended September 30,

 
   

2021

   

2020

 

Net Loss

  $ (8,994,000 )   $ (13,862,000 )
                 

Deduct:

               

Interest expense

    (4,573,000 )     (6,377,000 )

Other income (expense)

    833,000       (6,000 )

Gain on extinguishment of debt

    652,000       --  

Loss from operations

  $ (5,906,000 )   $ (7,479,000 )
                 

Add:

               

Depreciation and amortization

    477,000       569,000  

Stock-based compensation expense

    2,449,000       615,000  

Adjusted EBITDA

  $ (2,980,000 )   $ (6,295,000 )

 

The adjusted EBITDA loss was $2,980,000 for the nine months ended September 30, 2021 compared to a loss of $6,295,000 for the nine months ended September 30, 2020, an increase of $3,315,000. The adjusted EBITDA improvement was primarily due to lower inventory reserve expense of approximately $3,300,000 primarily related to COVID-19 testing kits which was incurred in the nine months ended September 30, 2020. Additionally, the nine months ended September 30, 2020 also had approximately $325,000 less in legal expenses primarily due to the absence of legal and other expenses related to the Mavericks lawsuit, approximately $100,000 less due to a fixed asset impairment expense incurred in the nine months ended September 30, 2020 and approximately $125,000 less in patent expense in the nine months ended September 30, 2021 as compared to the same period in 2020. Offsetting these decreases was approximately $200,000 more incurred in consulting expenses.

 

 

ITEM 3. Quantitative and Qualitative Disclosures about Market Risk

 

ThermoGenesis Holdings is a smaller reporting company as defined by Rule 12b-2 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”) and is not required to provide information under this item.

 

ITEM 4. Controls and Procedures

 

The Company carried out an evaluation, under the supervision, and with the participation of management, including both the Company’s Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined by Exchange Act Rule 13a-15(e) or 15d-15(e)) as of September 30, 2021. Disclosure controls and procedures cover controls and other procedures that are designed to ensure that information required to be disclosed by the Company in reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that such information is accumulated and communicated to management, including the Chief Executive Officer and the Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Based upon that evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have both concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2021.

 

There were no changes in the Company’s internal controls over financial reporting that occurred during the three months ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting. Management believes that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within any company, have been detected.

 

 

PART II - OTHER INFORMATION

 

ITEM 1.

LEGAL PROCEEDINGS.

In the normal course of operations, we may have disagreements or disputes with distributors, vendors, employees or other parties. Such potential disputes are seen by management as a normal part of business and while the outcome of such disagreements and disputes cannot be predicted with certainty, we do not believe that any pending legal proceedings are material. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

 

ITEM 1A.

RISK FACTORS.

There have been no material changes to the risk factors relating to the Company set forth in f, “Item IA. Risk Factors” of its Annual Report on Form 10-K for the year ended December 31, 2020.

 

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

 

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES.

None.

 

ITEM 4.

MINE SAFETY DISCLOSURE.

Not applicable.

 

ITEM 5.

OTHER INFORMATION.

None.

 

ITEM 6.

EXHIBITS.

An index of exhibits is found on page 26 of this report.

 

 

Item 6.          Exhibits.

 

Exhibit No.

Description

31.1

Certification by the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2

Certification by the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32

Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act of 2002

101.INS

Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document

101.SCH

Inline XBRL Taxonomy Extension Schema Document

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document

104 Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

 

 

ThermoGenesis Holdings, Inc.

 

Signatures

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

ThermoGenesis Holdings, Inc.

(Registrant)

 
     
     

Dated: November 12, 2021

/s/ Xiaochun (Chris) Xu, Ph.D.

 
 

Xiaochun (Chris) Xu, Ph.D.

Chief Executive Officer

(Principal Executive Officer)

 
     
     

Dated: November 12, 2021

/s/ Jeffery Cauble

 
 

Jeffery Cauble

Chief Financial Officer

(Principal Financial Officer)

 

 

27
ThermoGenesis (NASDAQ:THMO)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more ThermoGenesis Charts.
ThermoGenesis (NASDAQ:THMO)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more ThermoGenesis Charts.